calcium lactate (OMT-111)
/ MetiMedi Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 17, 2023
A phase IIa study to evaluate the efficacy of OMT-111 in patients with metastatic colorectal cancer resistant to standard therapies
(ESSO 2023)
- "Three cases were judged as "possibly related" and were classified as adverse drug reactions (ADRs). Conclusions The results of the phase IIa study showed that OMT-111 has a comparable efficacy without severe toxicity for the patients with refractory metastatic colorectal cancer."
Clinical • Metastases • P2a data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
August 20, 2020
OMT-111 for Terminal Stage Solid Tumors
(clinicaltrials.gov)
- P2; N=78; Not yet recruiting; Sponsor: MetiMedi Pharmaceuticals
Clinical • New P2 trial • Breast Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1